Pfizer Inc. (NYSE:PFE)  reported that 20 abstracts for XELJANZ® will be showcased at the 2016 ACR/ARHP Yearly Meeting to be held from November 11 to November 16. Notably, data from the two key Phase 3 OPAL trials of tofacitinib, the only JAK inhibitor under probe for psoriatic arthritis will be showcased for the first time.

The highlights

OPAL Broaden will be showcased during a plenary session while OPAL Beyond will be showcased during an abstract poster session. Additionally, updated and new research for ‘XELJANZ’ in rheumatoid arthritis will be presented. Michael Corbo of Pfizer said that as part of their commitment to immunology and inflammation, they continue to advance leading science in the exploration of Janus kinase inhibition. The extensive data being showcased at this year’s ACR/AHRP yearly meeting expands upon company’s knowledge on the role of XELJANZ for the cure of rheumatoid arthritis and validates its potential, if passed, for the cure of psoriatic arthritis.

The rheumatoid arthritis presentations at this fiscal’s meeting covers new information on the benefit-risk profile of ‘XELJANZ’ as monotherapy; safety and efficacy evaluation of XELJANZ without or with concomitant utilization of glucocorticoids; probe in the cure of early RA; and data on time to response. Report being showcased at ACR on the safety and efficacy of long-term XELJANZ medication comprise real-world experience from a provisional assessment of an RA registry and revised data from a long-term extension trial up to 8 years.

Pfizer has witnessed its revenues drop at a steady rate in the past five years. The recent 3Q2016 results, announced on November 1, 2016 with earnings of $0.61 per share missing projections by $0.01 and revenue coming at $13.05 billion, left the investors unimpressed. The major reason for this performance is the loss of patent protection for ‘Lipitor statin’ in 2011.

The drug has been one of the best-selling drugs since last many years, and global sales in 2010 had touched $10.7 billion. In fact, $7.9 billion of total sales came from the U.S alone. The loss of a deal of these sales to generic competition has negatively impacted Pfizer.

Previous articleInvestigation For Investors In Stock Of Twitter Inc (NYSE:TWTR)
Next articleIAMGOLD Corp (USA)(NYSE:IAG) CEO On 3Q2016 Performance
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.